

# Agilent Workflow for Immunotherapy and Oncology

4 ottobre, 2021

## Live - Webinar

**Data:** Lunedì 4 Ottobre, 2021

**Orario:** 15:00 - 16:30

**Relatori:**

Emma Nora Di Capua, Ph.D.  
Product Specialist Italy  
Cell Analysis Division

Stefano Gabriele, Ph.D.  
Genomics Account Manager  
Diagnostics & Genomics Groups  
Agilent Technologies, Inc.

## Combining Time-Resolved Cell-Based Assays with Genome Editing Approaches

In this seminar, we will discuss how researchers are using Agilent Seahorse XF technology to monitor changes in cellular function including onco-metabolism, multi-omics approach and immune metabolism.

The great challenge of immune cell-based therapies is to safely engineer cells that have enhanced performance characteristics compared to native immune cells. CRISPR gene editing systems have emerged as highly effective surgical tools for modifying genomes in living cells with unprecedented ease.

To address the challenges of cell engineering, Agilent has brought together an innovative set of solutions that bring greater activity and accuracy to CRISPR editing. These solutions are combined with the ability to assess and validate the results on live-cell platforms that deliver relevant, time-resolved functional data.

Main topics:

- Seahorse overview
- Onco-metabolism
- Immune-metabolism
- CRISPR editing in immunotherapy

[Please register via this link](#)